VIDEO: Seladelpar improves markers of cholestasis in primary biliary cholangitis

In a video exclusive, Marlyn Mayo, MD, of the University of Texas Southwestern Medical Center, reported long-term treatment with seladelpar was safe and well-tolerated in reducing markers of cholestasis and hepatocellular injury.

Mayo said seladelpar, overall, has “very safe and strong efficacy that gets even stronger in the second year.”